AR037928A1 - Compuesto de 2-oxopirrolidin 3- sulfonamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento - Google Patents
Compuesto de 2-oxopirrolidin 3- sulfonamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamentoInfo
- Publication number
- AR037928A1 AR037928A1 ARP020105014A ARP020105014A AR037928A1 AR 037928 A1 AR037928 A1 AR 037928A1 AR P020105014 A ARP020105014 A AR P020105014A AR P020105014 A ARP020105014 A AR P020105014A AR 037928 A1 AR037928 A1 AR 037928A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nrarb
- heteroatom
- halogen
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Composición farmacéutica que comprende un compuesto de fórmula (1) junto con un vehículo y/o excipiente farmacéuticos. Uso de un compuesto de fórmula (1) para la fabricación de un medicamento para el tratamiento de un paciente que padece un trastorno susceptible de mejoría por un inhibidor del factor Xa. Reivindicación 1: Un compuesto de 2-oxopirrolidin 3-sulfonamida caracterizado porque tiene la fórmula (1) en la que :R1 representa un grupo seleccionado del grupo de fórmulas (2) cada uno de los cuales opcionalmente contiene otro heteroátomo N, Z representa un sustituyente opcional halógeno, -CH2NH2, -NRaRb o -CN, Z' representa un sustituyente opcional halógeno, -CH2NH2 o -CN, alk representa alquileno o alquenileno, T representa S, O o NH; R2 representa hidrógeno, -(alquil C1-3)CONRaRb, -(alquil C1-3)CO2(alquilo C1-4), -(alquil C1-3)morfolino, -CO2(alquilo C1-4) o -(alquil C1-3)CO2H; X representa fenilo, o un grupo heterocíclico aromático o no aromático de 5 o 6 miembros que contiene al menos un heteroátomo seleccionado de O, N o S, cada uno de los cuales está opcionalmente sustituido con 0-2 grupos seleccionados de halógeno, -CN, -alquilo C1-4, -alquenilo C2-4, -CF3, -NRaRb, -NO2, -N(alquil C1-4)(CHO), -NHCO(alquilo C1-4), -NHSO2Rc, (alquil C0-4)ORd, -C(O)Rc, -C(O)NRaRb, -S(O)nRc y -S(O)2NRaRb; Y representa (i) un sustituyente seleccionado de hidrógeno, halógeno, -CN, -alquilo C1-4, -alquenilo C2-4, -CF3, -NRaRb, -NO2, -N(alquil C1-4)(CHO), -NHCO(alquilo C1-4), -NHSO2Rc, (alquil C0-4)ORd, -C(O)Rc, -C(O)NRaRb, -S(O)nRc o -S(O)2NRaRb, o (ii) fenilo, o un grupo heterocíclico aromático o no aromático de 5 o 6 miembros que contiene al menos un heteroátomo seleccionado de O, N o S, cada uno de los cuales está opcionalmente sustituido con 0-2 grupos seleccionados de halógeno, -CN, -alquilo C1-4, -CF3, -(CH2)nRaRb, -(CH2)nN+RaRbCH2CONH2, (alquil C0-4)ORd, -C(O)Rc, -C(O)NRaRb, -S(O)nRc, -S(O)2NRaRb, =O, óxido a un anillo N, -CHO, -NO2 y -N(Ra)(SO2Rc); Ra y Rb representan independientemente hidrógeno, -alquilo C1-6, o junto con el átomo de N al cual están unidos forman un anillo heterocíclico de 5, 6 o 7 miembros que contiene opcionalmente otro heteroátomo seleccionado de O, N o S, opcionalmente sustituido con alquilo C1-4, y opcionalmente el heteroátomo S está sustituido con O, es decir, representa S(O)n; Rc representa -alquilo C1-6; Rd representa hidrógeno o -alquilo C1-6; n representa 0-2; y sus derivados farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0130705.7A GB0130705D0 (en) | 2001-12-21 | 2001-12-21 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037928A1 true AR037928A1 (es) | 2004-12-22 |
Family
ID=9928210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020105014A AR037928A1 (es) | 2001-12-21 | 2002-12-19 | Compuesto de 2-oxopirrolidin 3- sulfonamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento |
Country Status (23)
Country | Link |
---|---|
US (1) | US20050059726A1 (es) |
EP (1) | EP1456172A1 (es) |
JP (1) | JP2005519885A (es) |
KR (1) | KR20040072666A (es) |
CN (1) | CN100364971C (es) |
AR (1) | AR037928A1 (es) |
AU (1) | AU2002366747A1 (es) |
BR (1) | BR0215200A (es) |
CA (1) | CA2471461A1 (es) |
CO (1) | CO5590896A2 (es) |
GB (1) | GB0130705D0 (es) |
HU (1) | HUP0500137A2 (es) |
IL (1) | IL162454A0 (es) |
IS (1) | IS7316A (es) |
MX (1) | MXPA04006139A (es) |
MY (1) | MY141579A (es) |
NO (1) | NO20042990L (es) |
NZ (1) | NZ533129A (es) |
PL (1) | PL371008A1 (es) |
RU (1) | RU2318807C2 (es) |
TW (1) | TWI262075B (es) |
WO (1) | WO2003053925A1 (es) |
ZA (1) | ZA200404147B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
GB0314373D0 (en) | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
TW200524858A (en) * | 2003-06-19 | 2005-08-01 | Glaxo Group Ltd | Chemical compounds |
GB0314370D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
GB0314299D0 (en) | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
US7169795B2 (en) * | 2003-09-30 | 2007-01-30 | Bristol Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
CA2575359A1 (en) * | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
DE102004062544A1 (de) * | 2004-12-24 | 2006-07-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel |
DE102005008649A1 (de) * | 2005-02-25 | 2006-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Pyrrolidinone, deren Herstellung und deren Verwendung als Arzneimittel |
US20090099231A1 (en) * | 2005-04-11 | 2009-04-16 | John David Harling | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors |
JPWO2006137527A1 (ja) | 2005-06-23 | 2009-01-22 | 協和発酵キリン株式会社 | チアゾール誘導体 |
CA2617817C (en) | 2005-08-02 | 2014-05-27 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivatives for treating or preventing sleep disorders |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
AR058221A1 (es) * | 2005-11-24 | 2008-01-23 | Glaxo Group Ltd | Benzazepinas inhibidoras del factor xa, composicion farmaceutica que la comprende y su uso para fabricar un medicamento |
PL2012839T3 (pl) | 2006-04-07 | 2012-06-29 | Bactiguard Ab | Nowatorskie podłoża przeciwdrobnoustrojowe i ich zastosowania |
CA2662574A1 (en) * | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202344A (en) * | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
US6034093A (en) * | 1995-06-07 | 2000-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
US5731315A (en) * | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
US6025358A (en) * | 1998-06-11 | 2000-02-15 | G. D. Searle & Co. | Double prodrugs of potent GP IIb/IIIa antagonists |
GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US7169795B2 (en) * | 2003-09-30 | 2007-01-30 | Bristol Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
-
2001
- 2001-12-21 GB GBGB0130705.7A patent/GB0130705D0/en not_active Ceased
-
2002
- 2002-12-19 AR ARP020105014A patent/AR037928A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136597A patent/TWI262075B/zh not_active IP Right Cessation
- 2002-12-19 MY MYPI20024789A patent/MY141579A/en unknown
- 2002-12-20 CA CA002471461A patent/CA2471461A1/en not_active Abandoned
- 2002-12-20 RU RU2004122427/04A patent/RU2318807C2/ru not_active IP Right Cessation
- 2002-12-20 IL IL16245402A patent/IL162454A0/xx unknown
- 2002-12-20 KR KR10-2004-7009675A patent/KR20040072666A/ko not_active Application Discontinuation
- 2002-12-20 MX MXPA04006139A patent/MXPA04006139A/es active IP Right Grant
- 2002-12-20 WO PCT/EP2002/014826 patent/WO2003053925A1/en active Application Filing
- 2002-12-20 AU AU2002366747A patent/AU2002366747A1/en not_active Abandoned
- 2002-12-20 JP JP2003554642A patent/JP2005519885A/ja active Pending
- 2002-12-20 US US10/499,529 patent/US20050059726A1/en not_active Abandoned
- 2002-12-20 NZ NZ533129A patent/NZ533129A/en unknown
- 2002-12-20 BR BR0215200-2A patent/BR0215200A/pt not_active IP Right Cessation
- 2002-12-20 PL PL02371008A patent/PL371008A1/xx not_active Application Discontinuation
- 2002-12-20 CN CNB028282248A patent/CN100364971C/zh not_active Expired - Fee Related
- 2002-12-20 HU HU0500137A patent/HUP0500137A2/hu unknown
- 2002-12-20 EP EP02805350A patent/EP1456172A1/en not_active Withdrawn
-
2004
- 2004-05-27 ZA ZA200404147A patent/ZA200404147B/en unknown
- 2004-06-16 IS IS7316A patent/IS7316A/is unknown
- 2004-06-18 CO CO04057414A patent/CO5590896A2/es not_active Application Discontinuation
- 2004-07-13 NO NO20042990A patent/NO20042990L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1620434A (zh) | 2005-05-25 |
EP1456172A1 (en) | 2004-09-15 |
CA2471461A1 (en) | 2003-07-03 |
WO2003053925A1 (en) | 2003-07-03 |
ZA200404147B (en) | 2005-06-21 |
AU2002366747A1 (en) | 2003-07-09 |
RU2318807C2 (ru) | 2008-03-10 |
BR0215200A (pt) | 2004-10-13 |
MXPA04006139A (es) | 2004-11-01 |
US20050059726A1 (en) | 2005-03-17 |
JP2005519885A (ja) | 2005-07-07 |
GB0130705D0 (en) | 2002-02-06 |
PL371008A1 (en) | 2005-06-13 |
RU2004122427A (ru) | 2006-01-20 |
TWI262075B (en) | 2006-09-21 |
HUP0500137A2 (en) | 2006-02-28 |
IS7316A (is) | 2004-06-16 |
KR20040072666A (ko) | 2004-08-18 |
IL162454A0 (en) | 2005-11-20 |
CN100364971C (zh) | 2008-01-30 |
NO20042990L (no) | 2004-09-20 |
MY141579A (en) | 2010-05-14 |
NZ533129A (en) | 2006-12-22 |
CO5590896A2 (es) | 2005-12-30 |
TW200306178A (en) | 2003-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037928A1 (es) | Compuesto de 2-oxopirrolidin 3- sulfonamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
ATE12492T1 (de) | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
AR035349A1 (es) | Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos | |
AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
AR035497A1 (es) | Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos | |
AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
CO5261605A1 (es) | Compustos farmaceuticos | |
CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
AR013815A1 (es) | NUEVOS DERIVADOS DEL ACIDO 4-FORMIL-4, 4a, 5, 6, 7, 7a, 8, 8a-OCTAHIDRO- 7-METIL-3-(1-METILETIL)-1,4-METANO-S-INDACEN-3a(1H)-CARBOXILICO, UN PROCESOPARA SU PREPARACION, SU USO EN LA FABRICACION DE UN MEDICAMENTO Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. | |
ES2147223T3 (es) | Derivados de indol como agonistas de tipo 5-ht1. | |
AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
AR023681A1 (es) | Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento. | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR039226A2 (es) | Compuestos utiles como intermediarios de preparacion y procedimientos | |
AR044662A1 (es) | Compuestos de azetidina | |
AR008291A1 (es) | Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento. | |
DE3679378D1 (de) | 3-amino-dihydro-(1)-benzopyrane und benzothiopyrane. | |
SE8107387L (sv) | Nya fenylalkylaminer, framstellning derav och anvendning som lekemedel | |
DK420682A (da) | Fremgangsmaade til fremstilling af triazoloquinazoloner eller salte deraf | |
SE7714685L (sv) | Forfarande for framstellning av nya basiskt substituerade o-propyloximer samt deras anvendning sasom lekemedel | |
AR016036A1 (es) | Derivados de tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica y el uso de los mismos para la fabricacion de unmedicamento | |
HUT40649A (en) | Process for production of new esthers of derivatives of 4-hydroxi-kinolin-3-carbon substituated by carbon-chain containing in position-2 l-hydroxi group and medical preparatives containing thereof as active substance | |
NO165593C (no) | Analogifremgangsmaate ved fremstilling av nye tetracykliske indolderivater. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |